Expert Highlights Advances in Treatment Landscape for Advanced Bladder Carcinoma
Neal Shore, MD, discusses the current outlook for the treatment landscape in advanced or metastatic urothelial carcinoma.
Neal Shore, MD, director, Carolina Urologic Research Center, discusses the current outlook for the treatment landscape in advanced or metastatic urothelial carcinoma.
The landscape has evolved dramatically due, in part, to the increased understanding of advanced disease, which led to the approval of 5 encouraging checkpoint inhibitor therapies, and approval of other novel therapies as well. These are truly remarkable improvements, Shore says.
We have also gained improved understanding of the use of immunotherapy in the frontline, as well as in the second-line and maintenance settings for patients with metastatic urothelial carcinoma. Among other advances in the field, Shore highlights the approval of erdafitinib (Balversa) and enfortumab vedotin-ejfv (Padcev), and these therapies all provide expanded treatment options for patients with metastatic disease who either failed or weren’t candidates for radical cystectomy.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
Study Shows Desire for Bladder-Sparing Treatments in High-Risk NMIBC
April 2nd 2024In an interview with Targeted Oncology, Joseph M. Jacob, MD, discussed how bladder preservation is the top reason for refusal of radical cystectomy in the TAR-200 monotherapy cohort of the SunRISe-1 study.
Read More
